---
title: "Top Executive Makes Notable Move With Alpha Tau Medical Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295740666.md"
description: "Alpha Tau Medical CFO Raphi Levy sold 17,730 shares for $248,220 on August 12, 2026. H.C. Wainwright cited strong Q2 progress and upcoming pivotal trial data as positive catalysts. However, TipRanks' AI Analyst Spark rates the stock Neutral due to weak financial performance, including no revenue and widening losses, despite constructive technical signals and a YTD price increase of 188.28%."
datetime: "2026-08-13T02:15:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295740666.md)
  - [en](https://longbridge.com/en/news/295740666.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295740666.md)
generator: "portal-rs"
---

# Top Executive Makes Notable Move With Alpha Tau Medical Stock

New insider activity at Alpha Tau Medical Ltd ( (DRTS) ) has taken place on August 12, 2026.

Alpha Tau Medical Ltd has disclosed an insider transaction in which Chief Financial Officer Raphi Levy sold 17,730 shares of the company’s stock, generating proceeds of $248,220. This sale by a key executive highlights notable insider activity that investors may consider when evaluating the company’s recent trading dynamics and leadership’s positioning.

Alpha Tau Medical’s shares were influenced as H.C. Wainwright cited the company’s strong Q2 progress across multiple cancer indications and advancing pivotal trials, while also pointing to the long-term catalyst of pivotal Alpha DaRT data expected in late 2026. Sentiment was further shaped by groundbreaking combination-study efficacy and safety data, new U.S. partnerships, and strategic moves like a Tel Aviv dual listing and fresh interim financial disclosures, which together enhance visibility and funding flexibility despite ongoing losses.

**Spark’s Take on DRTS Stock**

According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, widening losses, and significant ongoing cash burn) and limited valuation support (negative P/E, no dividend yield provided). This is partially offset by constructive technical trend signals, with the stock trading above its 20/50/100/200-day moving averages.

To see Spark’s full report on DRTS stock,  
 click here. 

**More about Alpha Tau Medical Ltd**

**YTD Price Performance:** 188.28%

**Average Trading Volume:** 831,643

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $1.23B

### Related Stocks

- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)
- [DRTSW.US](https://longbridge.com/en/quote/DRTSW.US.md)

## Related News & Research

- [Alpha Tau completes enrollment in 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study](https://longbridge.com/en/news/297513505.md)
- [AI agents keep finding ways to bend the rules. Here are some of the wildest.](https://longbridge.com/en/news/298138114.md)
- [3 'Outperform' ETFs with 10%+ Upside Potential, According to the AI Analyst](https://longbridge.com/en/news/297964242.md)
- [Northland Securities Sticks to Their Buy Rating for Rezolve AI (RZLV)](https://longbridge.com/en/news/297930459.md)
- [3 Best ETFs to Buy with 10%+ Upside Potential, According to the AI Analyst](https://longbridge.com/en/news/298086466.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**